Compounds > kibdelomycin
Page last updated: 2024-11-13

kibdelomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

kibdelomycin: an antibiotic that inhibits both gyrase and DNA topoisomerase IV; isolated from Kibdelosporangium; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71463014
CHEMBL ID2205318
MeSH IDM000610479

Synonyms (3)

Synonym
CHEMBL2205318
kibdelomycin
bdbm50406470

Research Excerpts

Overview

Kibdelomycin is a recently discovered natural-product antibiotic. It inhibits bacterial growth by inhibiting the bacterial DNA replication enzymes DNA gyrase and topoisomerase IV.

ExcerptReferenceRelevance
"Kibdelomycin A is a potent inhibitor of DNA gyrase and topoisomerase IV, inhibits DNA synthesis and shows whole cell antibiotic activity, albeit, less potently than kibdelomycin."( Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
Allocco, J; de la Cruz, M; Donald, RG; Dorso, K; Genilloud, O; Goetz, MA; Martín, J; Onishi, R; Phillips, JW; Polishook, J; Salowe, S; Sigmund, J; Singh, SB; Smith, SK; Vicente, F; Wiltsie, J; Zink, DL, 2012)		2.54
"Kibdelomycin is a recently discovered natural-product antibiotic that inhibits bacterial growth by inhibiting the bacterial DNA replication enzymes DNA gyrase and topoisomerase IV."( Kibdelomycin is a bactericidal broad-spectrum aerobic antibacterial agent.
Balibar, CJ; Dayananth, P; Fukuda, Y; Garlisi, CG; Ha, S; Kishii, R; Lu, J; Singh, SB; Takei, M; Young, K, 2015)		2.58
"Kibdelomycin is a complex novel antibiotic, discovered by applying a highly sophisticated chemical-genetic Staphylococcus aureus Fitness Test (SaFT) approach, that inhibits the clinically established bacterial targets, gyrase and topoisomerase IV. "( Discovery and development of kibdelomycin, a new class of broad-spectrum antibiotics targeting the clinically proven bacterial type II topoisomerase.
Singh, SB, 2016)		2.17

Dosage Studied

ExcerptRelevanceReference
"56mg/kg by oral dosing without systemic exposure."( Discovery and development of kibdelomycin, a new class of broad-spectrum antibiotics targeting the clinically proven bacterial type II topoisomerase.
Singh, SB, 2016)		0.73
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA gyrase subunit BStaphylococcus aureusIC50 (µMol)0.00900.00401.50207.7000AID1359519; AID717074
DNA gyrase subunit AStaphylococcus aureusIC50 (µMol)0.00900.00401.98397.7000AID717074
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID717075Inhibition of Escherichia coli topoisomerase-42012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID717082Antibacterial activity against Enterococcus faecalis CL85162012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID1064473Antibacterial activity against Escherichia coli MB5746 harboring envA1/TolC efflux pump mutant assessed as growth inhibition after 20 hrs by agar dilution method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
New natural products as new leads for antibacterial drug discovery.
AID717071Inhibition of Escherichia coli ATPase activity of topoisomerase-42012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID717072Inhibition of Escherichia coli ATPase activity of DNA gyrase2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID717085Antibacterial activity against methicillin-sensitive Staphylococcus aureus MB 2865 in presence of 50% human serum2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID717073Inhibition of Staphylococcus aureus topoisomerase-42012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID1064474Antibacterial activity against Escherichia coli MB2884 assessed as growth inhibition after 20 hrs by agar dilution method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
New natural products as new leads for antibacterial drug discovery.
AID717076Inhibition of Escherichia coli DNA gyrase2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID717080Antibacterial activity against Haemophilus influenzae MB45722012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID717070Antibacterial activity against wild type Staphylococcus aureus MB 59572012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID717081Antibacterial activity against Bacillus subtilis MB9642012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID717084Antibacterial activity against methicillin-resistant Staphylococcus aureus COL MB 53932012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID717083Antibacterial activity against Streptococcus pneumoniae CL2883 in presence of 2.5% lysed horse blood2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID717067Antibacterial activity against ciprofloxacin-resistant Staphylococcus aureus MB 5785 (R34)2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID717068Antibacterial activity against coumermycin A1-resistant Staphylococcus aureus MB 5957/H7 harboring GyrB Gln136Glu, Ile175Thr, Leu455Ile mutant2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID717074Inhibition of Staphylococcus aureus DNA gyrase2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID717086Antibacterial activity against methicillin-sensitive Staphylococcus aureus MB 28652012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID717077Antifungal activity against Candida albicans MY10552012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID1064475Antibacterial activity against methicillin resistant Staphylococcus aureus COL MB5393 assessed as growth inhibition after 20 hrs by agar dilution method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
New natural products as new leads for antibacterial drug discovery.
AID717069Antibacterial activity against novobiocin-resistant Staphylococcus aureus MB 5957/A8 harboring GyrB ASP89Gly mutant2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID717078Antibacterial activity against Escherichia coli MB5746 expressing envA1, tolC2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID717066Antibacterial activity against ciprofloxacin-resistant Staphylococcus aureus MB 5786 (R35)2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID1359519Inhibition of Staphylococcus aureus GyrB2018European journal of medicinal chemistry, May-25, Volume: 152New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV.
AID717079Antibacterial activity against Escherichia coli MB28842012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID1064476Antibacterial activity against methicillin sensitive Staphylococcus aureus MB2865 assessed as growth inhibition after 20 hrs by agar dilution method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
New natural products as new leads for antibacterial drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (80.00)24.3611
2020's2 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.78 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (30.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (70.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		3.2110isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		2.0710aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		4.6270pyrrole;
secondary amine
indazoles
Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.		3.2110indazole
isoxazoles
Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.		3.2110isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
alpha-aminopyridine
alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.		3.2110
glucose, (beta-d)-isomer
beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.		2.3110D-glucopyranoseepitope;
mouse metabolite
oxazolidin-2-one
Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.		3.2110carbamate ester;
oxazolidinone		metabolite
garenoxacin
garenoxacin: a des-fluoro(6) quinolone with antibacterial activity. garenoxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid that is substituted by a cyclopropyl group at position 1, an oxo group at position 4, a (1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl group at position 7, and a difluoromethoxy group at position 8.		3.2110aromatic ether;
cyclopropanes;
isoindoles;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic		antibacterial drug;
non-steroidal anti-inflammatory drug
abt 492
WQ 3034: structure in first source		3.2110
myxovirescin a
myxovirescin A: from Myxococcus virescens; structure given in first source		3.1910
arylomycin a-c16
[no description available]		3.1910
novobiocin
Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.		2.4920carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols		antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent
azd0914
zoliflodacin: a DNA gyrase inhibitor for treatment of gonorrhea		3.2110
amycolamicin
amycolamicin: isolated from Amycolatopsis; structure in first source		7.3110
ConditionIndicatedRelationship StrengthStudiesTrials
Infections, Staphylococcal
[description not available]		02.0610
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		02.0610